MedTrace Logo

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

NCT06947668 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-03-12

No results posted yet for this study

Summary

Analysis of tumor tissue (which is already available in pathology) and collection of saliva/stool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.

Conditions

  • Squamous Cell Carcinoma of Oropharynx
  • Squamous Cell Carcinoma of the Hypopharynx
  • Larynx Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Marlen Haderlein, MD · Universitätsklinikum Erlangen, Strahlenklinik

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2030-06-01
Completion
2030-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06947668 on ClinicalTrials.gov